Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02550743 · ClinicalTrials.gov registry record · Phase 1
BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study
A Phase 1 study, sponsored by howard safran.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02550743: Clinical Trial Phase 1 study, sponsored by howard safran.
NCT02550743 is a Phase 1 study that was terminated before completion, run by howard safran. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02550743, a Phase 1 study, was terminated before completion, sponsored by howard safran.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The primary goal of this Brown University Oncology Research Group is to determine that a safe dose of BYL719 can be administered with capecitabine and radiation in patients with rectal cancer. Therefore, the threshold of success for this phase I study is to establish safety.
Interventions
- DRUG Capecitabine
- RADIATION Radiation
- DRUG BYL719
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-06-03 |
| Est. Completion | 2018-11-16 |
| Phase | Phase 1 |
Why NCT02550743 stopped before completion
NCT02550743 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 3 interventions - of which Capecitabine is the first listed.
NCT02550743 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02550743 about?
NCT02550743 is a clinical study titled "BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study". The primary goal of this Brown University Oncology Research Group is to determine that a safe dose of BYL719 can be administered with capecitabine and radiation in patients with rectal cancer. Therefore, the threshold of success for this phase I study is to establish safety.
What is the current status of trial NCT02550743?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2016-06-03. Estimated completion is 2018-11-16.
What interventions are being tested in trial NCT02550743?
The interventions under investigation include: Capecitabine (DRUG), Radiation (RADIATION), BYL719 (DRUG).
Who is sponsoring clinical trial NCT02550743?
This trial is sponsored by howard safran, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02550743's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI